Myrtelle Announces Presentation of Positive 6-month Post-Treatment Data in Its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy in Canavan Disease at the American Society of Gene and Cell Therapy 26th Annual Meeting
Wakefield, Mass., May, 16th, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
Article Date
May 16, 2023
This article is featured on another website.
Go to article
February 10, 2026
Kainova Therapeutics secures $CAD 32 million to accelerate the development of its immuno-oncology and inflammation portfolio.
February 10, 2026
Kainova Therapeutics secures $CAD 32 million to accelerate the development of its immuno-oncology and inflammation portfolio.
January 28, 2026
Navigating Clinical Trials in the Philippines and Malaysia: Insights and Opportunities
Due to a combination of large, diverse populations, effective healthcare infrastructure, and evolving regulatory and…
January 28, 2026
Navigating Clinical Trials in the Philippines and Malaysia: Insights and Opportunities
Due to a combination of large, diverse populations, effective healthcare infrastructure, and evolving regulatory and…